Valiant Organics Ltd Q3 FY2023 Concall Summary

Key Takeaways

• A reset year, not a base year: Revenue fell ~13% YoY in Q3 and ~3% over 9M, driven by a collapse in dyes and intermediates demand. Management explicitly warns against using FY23 as a benchmark.
• PAP is the single swing factor: The ramp-up of Para Amino Phenol (PAP) to an eventual 800–900 MT/month is the core of the FY24 growth and margin recovery story, but the shift from batch to semi-continuous process is still in trial.
• Margins crushed by volume, not just price: Realizations and volumes both fell, leaving plants under-utilized and fixed costs unabsorbed; raw material prices also rose faster than selling prices could adjust.
• Pharma is a pilot, not a profit centre yet: The new pharma intermediates plant is a campaign-based pilot, experimenting with products and operating models; meaningful revenue contribution is at least a few quarters away.
• What to watch next quarter: Whether PAP exits FY23 at the promised 500 MT/month, any sign of stabilization in OAP, and whether chlorination volumes begin their Q1 recovery toward 4,000 tons.

The PAP Ramp: Promise vs. Process Risk

• Volume trajectory: Production is currently at 400-plus MT/month, with a target to exit FY23 at least around 500 MT/month and then phase up to an optimum 800–900 MT/month during FY24.
• Process uncertainty: The company has abandoned the pursuit of a fully continuous process and is now testing a semi-continuous approach; even if that fails, the batch process alone can reach 800–1,000 MT/month.
• Margin impact contained: Once optimum volume is achieved, whether via continuous, semi-continuous or batch, management expects no significant margin difference, only minor operational variances.
• Customer offtake secured: At 80–85% capacity utilization, roughly 80% of PAP output can be absorbed by the subsidiary company, with the remaining 20% sold to external customers, and customer acquisition is ongoing.
• No extra capex needed: The ramp-up to full capacity is already incorporated in existing planning, and the shift from continuous to semi-continuous fits within the same capex envelope.

Mihir Shah: "Even If we don't make it to 100% fully continuous process, we will probably be close at somewhere around semi-continuous process. Worst case scenario, we will also continue as batch process only, but we will be able to still manufacture and reach around 800 to 1,000 metric tons per"

Demand & End-Market Weakness

• Dyes and intermediates in a deep trough: European customers are running at very low capacity utilization or have shut down entirely, and management expects it will take another six months for those markets to return to prior levels.
• Hydrogenation volumes fell 8% QoQ because a key product serves the dyes and intermediates chain where industry demand is very low; PAP also had some impact in one month.
• Chlorination recovery is nearer: Q4 will show improvement, but the return to 4,000-ton-plus volumes is expected only from Q1 of next year.
• Revenue mix shifting structurally: Hydrogenation's contribution is rising aggressively and will eat into the share of chlorination and ammonolysis combined; chlorination will recover from its subdued FY23 level but remain below FY22.
• Long-term end-user mix target (assuming no new products): pharma (PAP) ~25–30%, dyes and pigments ~20–25%, chlorination (agro) ~25–30%.

Mihir Shah: "I would not be much worried about couple of years later. What right now is the situation is where we need to kind of return back to, you know, it's on the downside, which we need to come up."

Margins: The Double Squeeze

• Volume and price both hit: Realizations came down alongside volumes, creating a double impact that made margins look diminished; fixed-cost under-absorption at two dyes-dependent plants compounded the squeeze.
• Raw material lag: Prices rose but raw material costs rose faster, and quarterly contracts mean the pass-through takes time, compressing margins in the interim.
• FY23 margin exit: Q4 margins may improve as raw materials have stabilized, but the full-year FY23 figure will be pulled down by weak Q1 and Q3; management is not targeting 18–20% for the current year.
• FY24 margin band: Conservative expectation of 18–20% EBITDA margin, with a long-term target of 20–22% once all products stabilize.
• Chlorination profitability: Exports help overall chlorination margins, but the product mix includes both margin-accretive and margin-dilutive items; the 20–22% target is an aggregate.

Mihir Shah: "EBITDA margin, so given the volatility, it is very difficult to put a number, but somewhere between 20%, 22% on the long term should be conservative enough for us to achieve."

Pharma & New Initiatives: Early Stage

• Pharma plant is a pilot: Production started in January, but the facility is a campaign-based multi-product plant where products change monthly; it is experimenting with whether specific products and operating models work for Valiant.
• Revenue potential unclear: Management hopes for ₹50–60 crores upward of revenue, but says it will take a quarter or two to give a better answer; asset turnover is targeted at close to 1x, but it is too early to comment.
• OAP still not stabilized: The company faced scaling issues, switched from one route to another, and is seeing some success in trial runs from plant-level technical changes, but the product is not yet fully resolved.
• OAP commercialization timeline: Management says to take it with a pinch of salt, but aims to close the year with some commercialization possible from Q1 next year.
• Product confidentiality: Management declined to disclose therapy indications or end-use details for pharma intermediates, citing confidentiality agreements with the customer.

Mihir Shah: "It's more of a pilot plant where we are experimenting if this product or if this way of operations works out for Valiant. And if that does, then we have more scope to expand into that."

Balance Sheet & Capital Allocation

• Debt reduction, not elimination: The company is not looking to take further loans in the near future; the repayment schedule runs until FY26, so becoming debt-free is unlikely in the short term, but decent accruals are expected once PAP starts.
• Future capex: If a large capex programme arises, the company would consider a term loan; the project selection threshold is at least 15–18% return, but decisions are made on an overall group basis.
• Dividends: Payouts will increase once future growth materializes.
• Valiant Laboratories IPO: Board approval taken for the IPO of the subsidiary (formerly Bharat Chemicals); management declined to share any details on products, financials, or timelines, citing competitive sensitivity and premature stage of discussions.

Guidance & Commitments

Key Metrics